Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

ConclusionsIn DMARD-naive patients, apremilast monotherapy improved PsA signs/symptoms over 52 weeks and was generally well tolerated.Trial registrationClinicalTrials.gov (http://clinicaltrials.gov), NCT01307423.
Source: Rheumatology - Category: Rheumatology Source Type: research